Bristol-Myers Squibb (BMY) Revenue — Quarter Ended Dec 31, 2023
Revenue for the quarter increased compared to the previous quarter and also rose relative to the same quarter last year. The improvement follows a period of sequential declines earlier in the fiscal year.
Key takeaway
Quarter ended Dec 31, 2023 · FY2023 Q4
Revenue for the quarter increased compared to the previous quarter and also rose relative to the same quarter last year. The improvement follows a period of sequential declines earlier in the fiscal year.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$11.5B
Revenue reported for this quarter.
Quarter-over-quarter
+4.7%
Change from the immediately preceding quarter.
Year-over-year
+0.6%
Change from the comparable year-ago quarter.
Trailing four quarters
$45B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2023 | $11.3B | -2.7% |
| Jun 30, 2023 | $11.2B | -5.6% |
| Sep 30, 2023 | $11B | -2.2% |
| Dec 31, 2023 | $11.5B | +0.6% |
Revenue performance
The quarter's revenue was higher than the immediately preceding quarter, reversing a trend of three consecutive quarterly decreases. The year-over-year change was also positive, though modest.
Quarterly comparison
Compared with the prior quarter, revenue grew by a percentage in the mid-single digits. Compared with the same quarter one year earlier, revenue improved by a smaller percentage.
What to watch
The company's net debt position improved from the prior year-end, reflecting shifts in cash balances and debt obligations.